Early antihepatitis C virus response with second-generation C200/C22 ELISA.
Detection of early antibody to hepatitis C virus (HCV) by a new second-generation C200/C22 anti-HCV enzyme-linked immunosorbent assay (ELISA) and a four-antigen recombinant immunoblot assay (4-RIBA) was compared with the first-generation anti-HCV C100 ELISA using sequential serum samples of 9 recipients who were infected with HCV, as detected by polymerase chain reaction after transfusion of blood products. Within 26 weeks after transfusion, 9/9 (100%) recipients seroconverted with C200/22 ELISA, and 6/9 (67%) seroconverted with C100 ELISA. Compared with C100 ELISA, C200/C22 ELISA seroconversion occurred simultaneously in 3 cases, 5-6 weeks earlier in 3 other cases, and 20 weeks earlier in 1 case. Seven of 9 (78%) recipients became positive, and 2/9 (22%) became indeterminate with 4-RIBA. In 8 cases with clinical posttransfusion hepatitis non-A, non-B (PTH-NANB), anti-HCV C200/C22 ELISA seroconversion occurred 2-17 (mean 6) weeks after the onset of hepatitis. In 6 cases of PTH-NANB, anti-HCV C100 ELISA seroconversion occurred 2-26 (mean 9) weeks after the onset of hepatitis. It is concluded that the second-generation C200/C22 ELISA is more sensitive than the C100 ELISA for the detection of antibody during early HCV infection. Indeterminate 4-RIBA results are found in the early phase of HCV infection.
van der Poel
C L
CL
Red Cross Blood Bank Amsterdam, The Netherlands.
Bresters
D
D
Reesink
H W
HW
Plaisier
A A
AA
Schaasberg
W
W
Leentvaar-Kuypers
A
A
Choo
Q L
QL
Quan
S
S
Polito
A
A
Houghton
M
M
D004797:Enzyme-Linked Immunosorbent Assay; D016174:Hepacivirus / Q000276:immunology*; D006508:Hepatitis Antibodies / Q000032:analysis* / Q000096:biosynthesis; D006526:Hepatitis C / Q000175:diagnosis / Q000276:immunology* / Q000635:transmission; D006801:Humans; D015151:Immunoblotting; D016133:Polymerase Chain Reaction; D011446:Prospective Studies; D013997:Time Factors; D065227:Transfusion Reaction
D006508:Hepatitis Antibodies